Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating CNS disorders and rare diseases.
Employees: 1-10
Total raised: $100M
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.05.2026 | - | $100M | - |
Mentions in press and media 11
| Date | Title | Description |
| 22.07.2026 | Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 | Jupiter Neurosciences secures perpetual exclusive U.S. rights to ALA-002 in a transaction valued at up to $100 million, expanding into a dual clinical-stage CNS company. The acquisition of ALA-002 adds an FDA-designated Novel Chemical Entit... |
| 08.07.2026 | Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson | BOARD COMMITTEE COMPOSITION (EFFECTIVE JUNE 26, 2026) Dr. Tomas J. Philipson joins Jupiter Neurosciences' Board, strengthening the Company's expertise in healthcare economics, FDA policy, and long-term shareholder value creation. Former Whi... |
| 27.05.2026 | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease | The RESET trial design as referenced on clinicaltrials.gov is summarized here. Jupiter advances JOTROL™ clinical development with active enrollment underway in Phase 2a Parkinson’s disease study. Investigational Oral Candidate JOTROL™ Addre... |
| 20.05.2026 | Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002 | Jupiter Neurosciences (NASDAQ: JUNS) moves to acquire exclusive U.S. rights to next-generation MDMA therapy candidate ALA-002. Jupiter expands CNS pipeline with proposed licensing deal targeting the emerging psychedelic therapeutics market.... |
| 08.04.2026 | Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board | Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. New advisory board appointments strengthen Jupiter’s push into a $1.5B nutraceutical market with sci... |
| 31.03.2026 | Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 | Jupiter Neurosciences (NASDAQ: JUNS) showcases JOTROL™ platform progress and investor growth strategy at Emerging Growth Conference 91. Jupiter highlights dual-path model targeting CNS disorders and longevity markets, positioning JOTROL™ as... |
| 02.03.2026 | Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 | Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ At BIO, Jupiter will discuss its FDA-cleared Phase IIa clinical program in Parkinson's disease. Advancing FDA-Cleared Phase IIa Parkinson's Program Targeting ... |
| 25.02.2026 | Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | Members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. Ju... |
| 23.02.2026 | Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | Repayment Commencement Deferred to April 1, 2026 The amendment does not introduce any new pricing provisions, reset features or additional financing commitments. Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosc... |
| 13.02.2026 | Jupiter Neurosciences Selected as B2i Digital Featured Company | Dual-Path Strategy Targets Neuroinflammation While Expanding its consumer product line Alongside its clinical program, Jupiter is expanding a consumer brand powered by its proprietary JOTROL™ enhanced resveratrol formulation. Clinical-Stage... |
Show more